Bookmarks
KEY FACTS
Terminology
Clinical Implications
Imaging Recommendations
TERMINOLOGY
Definitions
- Sonazoid
- US contrast agent manufactured by GE Healthcare AS, Oslo, Norway
- Sonazoid
CLINICAL IMPLICATIONS
Contrast Agent
Pharmacokinetics
Storage and Handling
DOSAGE AND ADMINISTRATION
Preparation Instructions
Injection Instructions
Manufacturer-Recommended Dosages
Dosage Variations
Technical Pitfalls and Challenges
PRECAUTIONS
Adverse Reactions
USE IN SPECIFIC POPULATIONS
Pregnancy
Lactation
Elderly Patients
Selected References
- Shimazu K et al: Identification of sentinel lymph nodes by contrast-enhanced ultrasonography with Sonazoid in patients with breast cancer: a feasibility study in three hospitals. Cancer Med. 6(8):1915-1922, 2017
- Miyamoto Y et al: Efficacy of sonazoid (perflubutane) for contrast-enhanced ultrasound in the differentiation of focal breast lesions: phase 3 multicenter clinical trial. AJR Am J Roentgenol. 202(4):W400-7, 2014
- Shekhar H et al: Modifying the size distribution of microbubble contrast agents for high-frequency subharmonic imaging. Med Phys. 40(8):082903, 2013
- Correas JM et al: Contrast enhanced ultrasound in the detection of liver metastases: a prospective multi-centre dose testing study using a perfluorobutane microbubble contrast agent (NC100100). Eur Radiol. 21(8):1739-46, 2011
- Moriyasu F et al: Efficacy of perflubutane microbubble-enhanced ultrasound in the characterization and detection of focal liver lesions: phase 3 multicenter clinical trial. AJR Am J Roentgenol. 193(1):86-95, 2009
- Edey AJ et al: Ultrasound imaging of liver metastases in the delayed parenchymal phase following administration of Sonazoid using a destructive mode technique (Agent Detection Imaging). Clinical Radiology 63:1112-1120, 2008
- Watanabe R et al: Mechanism of hepatic parenchyma-specific contrast of microbubble-based contrast agent for ultrasonography: microscopic studies in rat liver. Invest Radiol. 42(9):643-51, 2007
Related Anatomy
Loading...
Related Differential Diagnoses
Loading...
References
Tables
Tables
KEY FACTS
Terminology
Clinical Implications
Imaging Recommendations
TERMINOLOGY
Definitions
- Sonazoid
- US contrast agent manufactured by GE Healthcare AS, Oslo, Norway
- Sonazoid
CLINICAL IMPLICATIONS
Contrast Agent
Pharmacokinetics
Storage and Handling
DOSAGE AND ADMINISTRATION
Preparation Instructions
Injection Instructions
Manufacturer-Recommended Dosages
Dosage Variations
Technical Pitfalls and Challenges
PRECAUTIONS
Adverse Reactions
USE IN SPECIFIC POPULATIONS
Pregnancy
Lactation
Elderly Patients
Selected References
- Shimazu K et al: Identification of sentinel lymph nodes by contrast-enhanced ultrasonography with Sonazoid in patients with breast cancer: a feasibility study in three hospitals. Cancer Med. 6(8):1915-1922, 2017
- Miyamoto Y et al: Efficacy of sonazoid (perflubutane) for contrast-enhanced ultrasound in the differentiation of focal breast lesions: phase 3 multicenter clinical trial. AJR Am J Roentgenol. 202(4):W400-7, 2014
- Shekhar H et al: Modifying the size distribution of microbubble contrast agents for high-frequency subharmonic imaging. Med Phys. 40(8):082903, 2013
- Correas JM et al: Contrast enhanced ultrasound in the detection of liver metastases: a prospective multi-centre dose testing study using a perfluorobutane microbubble contrast agent (NC100100). Eur Radiol. 21(8):1739-46, 2011
- Moriyasu F et al: Efficacy of perflubutane microbubble-enhanced ultrasound in the characterization and detection of focal liver lesions: phase 3 multicenter clinical trial. AJR Am J Roentgenol. 193(1):86-95, 2009
- Edey AJ et al: Ultrasound imaging of liver metastases in the delayed parenchymal phase following administration of Sonazoid using a destructive mode technique (Agent Detection Imaging). Clinical Radiology 63:1112-1120, 2008
- Watanabe R et al: Mechanism of hepatic parenchyma-specific contrast of microbubble-based contrast agent for ultrasonography: microscopic studies in rat liver. Invest Radiol. 42(9):643-51, 2007
